Trial Profile
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Renal Impairment Compared to Subjects With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis; Cerebral infarction; Liver disorders; Stroke
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma America
- 28 Aug 2020 Primary endpoint . (AUC0-) has not been met according to the results published in the Clinical Therapeutics
- 28 Aug 2020 Primary endpoint (AUC0-last) has not been met according to the results published in the Clinical Therapeutics
- 28 Aug 2020 Primary endpoint (Cmax) has not been met according to the results published in the Clinical Therapeutics